Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
20+ Years of The DRCR Network: What We Have Learned About Diabetic Retinopathy
John W. Kitchens, MD
Updates from the Field
2025
Association Between Early Vision-Related Quality of Life (QoL) Outcomes and Anatomic Dryness in neovascular AMD and DME in the VIEW and FAME trials
Michael A. Singer, MD
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more